gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma: Results of a Phase I Clinical Trial

Meeting Abstract

  • corresponding author presenting/speaker Wolfram Pönisch - Universität Leipzig, Deutschland
  • Marta Rozanski - Universität Leipzig
  • Hartmut Goldschmidt - Universität Heidelberg
  • Franz Albert Hoffmann - Arztpraxis Leipzig
  • Thomas Boldt - KH Dresden-Friedrichstadt
  • Ute Ruffert - Arztpraxis Jena
  • Robert Rohrberg - Gemeinschaftspraxis Halle
  • Andreas Schwarzer - Gemeinschaftspraxis Leipzig
  • Elke Schwalbe - Klinikum Dessau
  • Ute Kreibich - KH Zwickau
  • Ursula Haak - KH Martha Maria Halle
  • Dietger Niederwieser - Universität Leipzig

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO113

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk223.shtml

Veröffentlicht: 20. März 2006

© 2006 Pönisch et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Thalidomide is an active single agent in advanced relapsed or refractory multiple myeloma (MM). Treatment, however, is associated with significant dose-dependent toxicity limiting his application. Combination of low dose thalidomide with bendamustine and prednisolone might be a way to maintain efficacy of the drug without dose limiting toxicity (DLT). The treatment consists of a fixed dose of bendamustine (60mg/qm) day 1, 8, and 15 and prednisolone (100 mg) day 1, 8, 15, and 22. At the same time, thalidomide was given in patients cohorts with escalating doses, starting with 50 mg to a maximum of 200 mg daily. 8 patients (4 after conventional chemotherapy and 4 after APBSCT) were enrolled at each dose level. Cycles were repeated every 28 days for a minimum of 2 and a maximum of 10 cycles until a maximal response was achieved, a DLT or a disease progression were observed. 23 patients ( 8 in the first dose level with 50 mg thalidomide, 8 in the second dose level with 100 mg and 7 patients in the third dose level with 200 mg) are enrolled until now. The number of prior treatment regimens was 2 or more in all patients. 6 patients were refractory for the last treatment. Median age was 67 years (range: 40 – 78). All patients completed 2 cycles of BPT-treatment (11 completed 6 cycles or more, 5 completed 5 cycles, 2 completed 4 cycles, 3 completed 3 cycles and 2 completed 2 cycles) and were hence evaluable. Response was assessed using EBMT criteria modified to include near complete remission (nCR) and very good partial remission (VGPR). 20 of 23 patients responded after at least 2 cycles of chemotherapy with 3 CR, 5 VGPR, 9 PR and 3 MR. 3 patients had stable disease. No DLT was observed in the three doses level. Most common site effects were constipation (10 patients WHO grade 1, 8 patients WHO grade 2), polyneuropathy (14 patients WHO grade 1, 2 patients WHO grade 2) and somnolence (4 patients WHO grade 1). None of the 23 patients developed dose-limiting hematoxicity as defined by an ANC < 1,0 Gpt/l for > 7 days or an ANC < 0,5 Gpt/l for > 3 days or platelet count < 25 Gpt/l. Short neutropenia was reported in 8 patients (WHO grade 3 and 4) but no thrombocytopenia was observed. No grade 3 or 4 non-hematological toxicity was encountered and no dose modification was required. BPT with a dose between 50 and 200 mg thalidomide daily is well tolerated in patients with relapsed or refractory MM.